OTCMKTS:ZLDPF Zealand Pharma A/S Q2 2025 Earnings Results & Report $34.00 0.00 (0.00%) As of 10/15/2026 10:37 AM Eastern Zealand Pharma A/S missed analyst expectations on both earnings and revenue in its Q2 2025 results, released August 14, 2025. The company reported EPS of $16.06 versus the $16.72 consensus estimate, while revenue of $1.43 billion fell short of the $9.18 billion estimate by $7.75 billion. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market Opens Zealand Pharma A/S EPS ResultsActual EPS$16.06Consensus EPS $16.72Beat/MissMissed by -$0.66One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersZealand Pharma A/S Revenue ResultsActual Revenue$1.43 billionExpected Revenue$9.18 billionBeat/MissMissed by -$7.75 billionYoY Revenue GrowthN/AUpcoming EarningsZealand Pharma A/S' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Zealand Pharma A/S Q2 2025 Earnings FAQ Did Zealand Pharma A/S beat earnings estimates for Q2 2025? Zealand Pharma A/S (OTCMKTS:ZLDPF) reported earnings of $16.06 per share for Q2 2025, missing the consensus estimate of $16.72. The report was announced on Thursday, August 14, 2025. What was Zealand Pharma A/S' revenue for Q2 2025? Zealand Pharma A/S reported revenue of $1.43 billion for Q2 2025, against a consensus estimate of $9.18 billion. When is Zealand Pharma A/S' next earnings date? Zealand Pharma A/S' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zealand Pharma A/S on the company's earnings history page. Zealand Pharma A/S Earnings HeadlinesZealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low - Time to Sell?October 16 at 3:41 AM | americanbankingnews.comZealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 1-Year Low - Time to Sell?October 10, 2026 | americanbankingnews.comI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.October 16 at 1:00 AM | Behind the Markets (Ad)Zealand, Roche release phase 2 topline data for amylin analogue petrelintideOctober 8, 2026 | msn.comPetrelintide Phase III Trial Puts Zealand Pharma in the Obesity–Heart Disease SpotlightOctober 7, 2026 | tipranks.comZealand Pharma Advances Petrelintide Into Phase III, Raising Its Profile in the Obesity Drug RaceOctober 7, 2026 | tipranks.comSee More Zealand Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email. Email Address About Zealand Pharma A/SZealand Pharma A/S (OTCMKTS:ZLDPF) is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery. Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes. The company has also developed several investigational medicines, including petrelintide, an amylin analog being studied for weight management, and other peptide-based candidates for metabolic and gastrointestinal conditions. Zealand previously discovered lixisenatide, which was developed and commercialized through a collaboration with Sanofi under the names Adlyxin and Lyxumia. Founded in 1998, Zealand Pharma serves international markets through its own activities and collaborations with pharmaceutical partners. Its development programs have included partnerships with companies such as Boehringer Ingelheim, particularly in obesity and related metabolic diseases. Zealand is led by President and Chief Executive Officer Adam Steensberg and is headquartered in Søborg, Denmark.View Zealand Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
